GSKGSK plc

NYSE gsk.com


$ 41.35 $ 0.47 (1.15 %)    

Tuesday, 04-Jun-2024 15:59:53 EDT
QQQ $ 454.82 $ 1.24 (0.27 %)
DIA $ 398.57 $ 1.27 (0.33 %)
SPY $ 530.36 $ 0.59 (0.11 %)
TLT $ 91.26 $ 1.07 (1.17 %)
GLD $ 225.37 $ -1.95 (-0.9 %)
$ 41.35
$ 41.31
$ 41.24 x 100
$ 41.37 x 100
$ 41.04 - $ 41.46
$ 32.12 - $ 45.80
5,469,440
na
89.15B
$ 0.53
$ 14.20
TBD
na
na ($ 0.05)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 gsks-blenrep-combo-therapy-cuts-risk-of-disease-progression-or-death-by-around-50-in-pretreated-multiple-myeloma

GSK presented interim results from the DREAMM-8 phase 3 trial at ASCO 2024. Blenrep (belantamab mafodotin) with PomDex showed a...

 zantac-heart-burn-continues-for-gsk-as-us-court-ruling-allows-thousands-of-zantac-lawsuits-to-move-forward

GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (rani...

 saturday-gsk-said-it-disagrees-with-ruling-by-delaware-state-court-that-contradicts--federal-courts-multidistrict-litigation-ruling-which-dismissed-all-cases-alleging-five-cancer-types-in-december-2022-gsk-said-it-will-immediately-seek-an-appeal

https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation-delaware-state-court-daubert-ruling/

 reported-earlier-gsks-interim-analysis-of-the-dreamm-8-phase-iii-head-to-head-trial-evaluating-belantamab-mafodotin-combination-shows-50-reduction-in-disease-progression-risk-in-multiple-myeloma

DREAMM-8 phase III trial showed statistically significant and clinically meaningful improvement in primary endpoint of progre...

 goldman-sachs-initiates-coverage-on-gsk-with-neutral-rating-announces-price-target-of-47

Goldman Sachs analyst Rajan Sharma initiates coverage on GSK (NYSE:GSK) with a Neutral rating and announces Price Target of ...

 astrazeneca-merck-gsk-struck-record-441b-licensing-deals-with-chinese-drugmakers-in-2023-report

Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers.

 zantac-verdict-jury-finds-no-link-to-colon-cancer-in-initial-trial-gsk-and-boehringer-prevail-in-first-zantac-cancer-lawsuit

Chicago jury rejects woman's claim that Zantac caused her colon cancer. First of thousands of similar lawsuits, companies d...

 jury-rules-zantac-not-a-cause-of-womans-cancer-in-first-trial-over-drug

- Reuters

 first-advanced-oral-treatment-for-asthma---sanofis-investigational-drug-shows-potential

Sanofi reveals Phase 2 results for rilzabrutinib in moderate-to-severe asthma. High and low doses showed a reduction in asthma ...

 gsk-concealed-risk-associated-with-discontinued-heart-burn-drug-zantac-whistleblower-lawsuit-claims

Valisure sues GSK accusing the company of hiding cancer risks linked to Zantac, potentially defrauding the U.S. government. Thi...

 gsks-experimental-asthma-drug-reduces-severe-attacks-phase-3-trial-data-shows

GSK announced results from phase 3 trials SWIFT-1 and SWIFT-2, showing depemokimab's efficacy and safety in reducing severe...

 gsk-faces-whistleblower-suit-from-lab-that-exposed-zantac-risk-wisner-moore-to-represent-valisure-in-case-valisure-claims-gsk-hid-drug-risks-while-us-paid-for-zantac

-Bloomberg

 gsk-completely-exits-sensodyne-toothpaste-maker-haleon-in-16b-sale

GSK is fully exiting its position and will no longer hold any ordinary shares in Haleon, maker of Sensodyne toothpaste and Advi...

Core News & Articles

GSK plc (LSE/NYSE: GSK) today announced that it intends to sell approximately 385m ordinary shares in Haleon, equivalent to app...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION